Retiro De Equipo (Recall) de Lotus Valve System (a transcatheter aortic valve implantation (TAVI) system) Lotus TAVR 23mm

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Boston Scientific Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
  • ID del evento
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Boston scientific’s (bsc) review of the post-market data has identified an increase in the number of complaints related to ‘catheter release pin mandrel break’. the failure can occur during sheathing as part of device preparation or re-sheathing during the procedure, if repositioning is required. the release mandrel break is most commonly identified during the valve releasing phase of the procedure. in the event of a broken release mandrel, the physician will re-sheath the valve and replace the device. in addition to the 24 complaints reported during nov 2014 – jan 2016, there were 8 complaints reported in february 2016 related to release mandrel. there has been one complaint event reported in february 2016 which resulted in a patient death. bsc’s investigation concluded that incorrect preparation of a device may contribute to increased opportunity for the release mandrel to break.
  • Acción
    Boston Scientific (BSC) is initiating this action to: 1- Provide additional clarification on the instructions for preparing the Lotus Valve System prior to the procedure; and 2- Ensure all certified physicians have received all training necessary for independent implantation of the device, i.e., without the support of a BSC Field Clinical Specialist (FCS). Boston Scientific is advising users that the relevant training manuals have been updated to avoid crimping the mid-section of the valve during sheathing. Boston Scientific Field Clinical Specialist will re-train all cath-lab staff in the revised procedures. Users in "Non Independent" sites are reminded to ensure all procedures are completed with the support of a Boston Scientific Field Clinical Specialist until the site has been designated to be "Independent" by Boston Scientific. This action has been closed-out on 30/01/2017.


  • Modelo / Serial
    Lotus Valve System (a transcatheter aortic valve implantation (TAVI) system) Lotus TAVR 23mmMaterial Number: H749LTV230Catalogue Number: LTV23All batches affectedLotus TAVR 25mmMaterial Number: H749LTV250Catalogue Number: LTV25All batches affectedLotus TAVR 27mmMaterial Number: H749LTV270Catalogue Number: LTV27All batches affectedARTG Number: 260448
  • Manufacturer


  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source